Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

France’s Sanofi has entered into an exclusive licensing agreement with US biotechnology company RadioMedix and French biotechnology company Orano ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. /PRNewswire/ -- USA News Group – Cancer rates are rising glob ...

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple ... Sanofi's Sarclisa infusion as a treatment ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...